Current Controversies in Oncology
Current Controversies in Oncology and Current Insights in Oncology articles provide a forum for the exchange of views on topical issues in the field of oncology. The opinions expressed are those of the authors alone. They do not necessarily reflect the views of the Editor or ASCO.
Jun 02, 2011
Experts discuss developing and implementing breast cancer surveillance recommendations for childhood survivors of cancer in the United Kingdom and the United States
Mar 28, 2011
"While breast cancer is relatively uncommon in young adults, women increasingly delay pregnancy and childbirth into their fourth decade of life, and sometimes into their 40s. Consequently, we have seen . . . an increase in the frequency of breast cancer diagnosed during pregnancy."
Jan 04, 2011
"Two well-designed and conducted phase II clinical trials have rather convincingly revealed that single-agent bevacizumab possesses considerable biological activity in recurrent and platinum-resistant ovarian cancer. Further, one of these second-line studies demonstrated that . . ."
Sep 22, 2010
"Radiation therapy in pure germinoma is indispensable in providing a cure. Chemotherapy alone cannot replace radiation therapy as sole treatment and can only be performed in a combined setting."
Jun 28, 2010
"The recent prospective observational study in the Nurses’ Health Study by Holmes et al. (2010) provides support for the use of aspirin after a diagnosis of breast cancer. The study population consisted of 4,164 female registered nurses between ages 30-55 at baseline in 1976. . ."
May 14, 2010
"Patients with metastatic cancer are often faced with an ultimately fatal disease. This often causes patients to consider any therapy that may be construed as providing any chance for improved survival. The stress of their situation may also make patients less able to evaluate data."
Apr 23, 2010
"CA125 measurements are very useful blood tests for . . . for the majority of patients with epithelial ovarian cancer. However, the value of CA125 levels to follow patients who are in clinical remission after first-line chemotherapy recently has been challenged in a study . . ."